RNA Interference: a Promising Therapy for Gastric Cancer

Felipe, Aledson Vitor; Oliveira, Juliana de; Chang, Paula Yun Joo; Moraes, Andrea Aparecida; Silva, Tiago Donizetti da; Tucci-Viegas, Vanina Monique; Forones, Nora Manoukian

doi:10.7314/apjcp.2014.15.14.5509

Cited by 9 publications

(8 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At present, small interfering RNA (siRNA)-mediated gene regulation or therapy has shown immense potential in treating various diseases by silencing abnormally up-regulated genes [4-6]. In this kind of gene therapy, siRNA could be delivered into cells utilizing either viral vectors or non-viral carriers, causing degradation of targeted mRNA and subsequently leading to the silence of specific protein expression [7]. The success of gene therapy is largely dependent on the development of a safe and efficient gene delivery system [8-10].…”

Section: Introductionmentioning

confidence: 99%

A promising gene delivery system developed from PEGylated MoS2 nanosheets for gene therapy

et al. 2014

View full text Add to dashboard Cite

A new class of two-dimensional (2D) nanomaterial, transition metal dichalcogenides (TMDCs) such as MoS2, MoSe2, WS2, and WSe2 which have fantastic physical and chemical properties, has drawn tremendous attention in different fields recently. Herein, we for the first time take advantage of the great potential of MoS2 with well-engineered surface as a novel type of 2D nanocarriers for gene delivery and therapy of cancer. In our system, positively charged MoS2-PEG-PEI is synthesized with lipoic acid-modified polyethylene glycol (LA-PEG) and branched polyethylenimine (PEI). The amino end of positively charged nanomaterials can bind to the negatively charged small interfering RNA (siRNA). After detection of physical and chemical characteristics of the nanomaterial, cell toxicity was evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Polo-like kinase 1 (PLK1) was investigated as a well-known oncogene, which was a critical regulator of cell cycle transmission at multiple levels. Through knockdown of PLK1 with siRNA carried by novel nanovector, qPCR and Western blot were used to measure the interfering efficiency; apoptosis assay was used to detect the transfection effect of PLK1. All results showed that the novel nanocarrier revealed good biocompatibility, reduced cytotoxicity, as well as high gene-carrying ability without serum interference, thus would have great potential for gene delivery and therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

A promising gene delivery system developed from PEGylated MoS2 nanosheets for gene therapy

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Tang J., Zhuang S., 2015;Reddy MA, Natarajan R., 2015). Analyzed advantageous methods for treating cancer, completely based on the management epigenetic mechanisms using synthetic microRNA (Tan W. et al, 2014;. Felipe AV et al, 2014.).…”

Section: Oncological Aspects Of Expression Of the Components Pac And mentioning

confidence: 99%

Expression of the Components of the Renin-Angiotensin System in Oncological Diseases

Dolomatov¹,

Zukow²,

Novikov³

et al. 2018

Preprint

View full text Add to dashboard Cite

Analyzed the literature devoted to the changes in the expression of the RAS proteins of cancer cells. A brief review of protein expression dynamics PAC in malignant tumors and the possible role of epigenetic mechanisms in these processes. Through research epigenetic mechanisms state for cancer have been developed principally new techniques for their correction, based on the use of selective regulators systems covalent modification-histone proteins (for example, deacetylase inhibitor) and microRNA synthesis technologies. Literature data show promising pharmacological correction epigenetic modification of chromatin in the treatment of cancer.

show abstract

“…One of the key reasons for the poor prognosis of patients with GC is its character of invasion and metastasis, which has been observed to occur in >60% of patients at the point of diagnosis (4)(5)(6). Therefore, it's important to understand the molecular basis of GC invasion and metastasis in order to develop novel therapeutic strategies for GC (7). The discovery of microRNAs (miRNAs) is a significant milestone in the investigation of cancer, including GC (8).…”

Section: Introductionmentioning

confidence: 99%

“…miRNA-protein complexes can bind to the mRNA of target genes, leading to degradation or translational inhibition of target genes, which controls a wide range of biological functions, including cell proliferation, differentiation and apoptosis (8)(9)(10). miRNAs have been a major focus in studies investigating cancer (4,7,11,12). Increasing evidence indicates that miRNAs have paradoxical functions and act in a cell context-dependent manner (13,14).…”

Section: Introductionmentioning

confidence: 99%

MicroRNA-34a attenuates the proliferation, invasion and metastasis of gastric cancer cells via downregulation of MET

Wei

Huang

et al. 2015

Molecular Medicine Reports

View full text Add to dashboard Cite

Proliferation, invasion and metastasis are key features of gastric cancer, contributing to high mortality rates in patients with gastric cancer worldwide. As a direct target of p53, the functions of microRNA (miR)‑34a are important, but controversial, in the progression of gastric cancer. In the present study, the clinical importance of miR‑34a in GC specimens (n=40) were investigated and were confirmed in an independent cohort from The Cancer Genome Atlas (TCGA; n=352). The prognostic value of miR‑34a was analyzed using a Kaplan‑Meier survival curve in the TCGA cohort, in combination with complete follow‑up data (n=157). The level of miR‑34a was detected in the human gastric cancer cell line and normal gastric epithelial cell line. The effect of miR‑34a on proliferation and invasion were evaluated using Cell Counting Kit 8, colony formation and cell invasion assays. The molecular basis of miR‑34a was determined by bioinformatics prediction. The correlation between miR‑34a and MET was assessed using reverse transcription‑quantitative polymerase chain reaction and western blot analyses. The results indicated that miR‑34a was downregulated in the gastric cancer tissues, compared with the normal gastric tissues (P<0.01). miR‑34a was negatively correlated with the depth of invasion and lymph node metastasis of gastric cancer (P<0.01). In the TCGA cohort, the levels of miR‑34a were lower in T3 and T4 tumor stages, compared with the level in the T1 stage, and low levels of miR‑34a predicted significantly longer survival rates in patients with GC (P<0.05). miR‑34a also attenuated the proliferation ability, and inhibited the colony formation and cell invasion abilities of the cells (P<0.01). A negative correlation was observed between miR‑34a and MET in gastric cancer (P<0.01; r=‑0.9526), and >60% of cases exhibited consistent expression of miR‑34a and MET in gastric cancer (P<0.01). In conclusion, miR‑34a was associated with the clinicopathological features of gastric cancer and was a valuable predictor of patient prognosis. miR‑34a acted as a tumor suppressor to inhibit gastric cancer proliferation and invasion via the downregulation of MET.

show abstract

RNA Interference: a Promising Therapy for Gastric Cancer

Cited by 9 publications

References 70 publications

A promising gene delivery system developed from PEGylated MoS2 nanosheets for gene therapy

A promising gene delivery system developed from PEGylated MoS2 nanosheets for gene therapy

Expression of the Components of the Renin-Angiotensin System in Oncological Diseases

MicroRNA-34a attenuates the proliferation, invasion and metastasis of gastric cancer cells via downregulation of MET

Contact Info

Product

Resources

About